Keita Nakamori

Keita Nakamori

Auto-generated profile, based on publicly available information

Keita Nakamori

Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2022 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
TUTaizo Uchimoto
Taizo Uchimoto
KNKo Nakamura
Ko Nakamura
KKKazumasa Komura
Kazumasa Komura
WFWataru Fukuokaya
Wataru Fukuokaya
YYYusuke Yano
Yusuke Yano
HAHaruhito Azuma
Haruhito Azuma

3 August 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
YXYao Xiao
Yao Xiao
ASAndreas Schroeter
Andreas Schroeter
FMFriederike Martin
Friederike Martin
TMTomohisa Matsunaga
Tomohisa Matsunaga
KNKeita Nakamori
Keita Nakamori
STStefan G. Tullius
Stefan G. Tullius
Biological sex affects immunity broadly with recognized effects on incidence and severity of autoimmune diseases, infections and malignancies. Consequences of sex on alloimmunity and outcomes in solid organ transplantation are less well defined. Clinical studies have shown that donor and recipient sex independently impact transplant outcomes both, which are further modified by aging. Potential mechanisms have thus far not been detailed and may include hormonal, genetic and epigenetic components. Here, we summarize relevant findings in immunity in addition to studies in clinical and experimental organ transplantation detailing effects of biological sex on alloimmunity. Understanding both clinical impact and mechanisms is expected to provide critical insights on the complexity of alloimmune responses with the potential to fine-tune treatment and allocation while providing a rationale to include both sexes in transplant research.

2 July 2026 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
TTTakuya Tsujino
Takuya Tsujino
SYShogo Yamazaki
Shogo Yamazaki
MSMoritoshi Sakamoto
Moritoshi Sakamoto
YYYuki Yoshikawa
Yuki Yoshikawa
RMRyoichi Maenosono
Ryoichi Maenosono
HAHaruhito Azuma
Haruhito Azuma
Bladder-preserving trimodality therapy (TMT) incorporating concurrent chemoradiotherapy (CRT) provides a curative-intent alternative to radical cystectomy for muscle-invasive bladder cancer (MIBC), yet its efficacy is frequently limited by intrinsic treatment resistance, the molecular basis of which remains poorly defined. To address this, we performed bulk transcriptomic profiling of pretreatment tumors from 179 patients uniformly treated with bladder-preserving CRT and systematically integrated gene expression data with tumor immune features and clinical outcomes. We identified a ferroptosis-suppressive transcriptional signature (FSS) associated with a distinct resistance-associated tumor state that independently stratified radiographic progression-free survival and overall survival following CRT. FSS-high tumors were characterized by inferior outcomes, enrichment of basal/squamous and immune-excluded phenotypes, and reduced intratumoral immune infiltration, whereas FSS-low tumors preferentially exhibited luminal unstable and immune-inflamed features. Consistent with clinical observations, a ferroptosis-suppressive transcriptional program was recapitulated in CRT-resistant bladder cancer cell line models. Genome-wide CRISPR/Cas9 loss-of-function screening further identified core ferroptosis suppressors as functionally relevant dependencies specifically under irradiation stress, and pharmacologic induction of ferroptosis effectively restored radiosensitivity in otherwise resistant cells. Together, these findings support ferroptosis suppression as a biologically relevant resistance-associated state that mechanistically links tumor-intrinsic transcriptional programs to immune contexture and therapeutic vulnerability and provide a translational framework for improved risk stratification and future treatment refinement in bladder-preserving therapy for MIBC.

1 January 2026 in Case Reports in Transplantation
Verified
Journal Article
Open access
TOTomota Okabe
Tomota Okabe
YNYuki Nakajima
Yuki Nakajima
KIKengo Iwatsuki
Kengo Iwatsuki
RMRyoichi Maenosono
Ryoichi Maenosono
TMTakuya Matsuda
Takuya Matsuda
HAHaruhito Azuma
Haruhito Azuma
Nail‐patella syndrome (NPS) is a rare disease characterized by fingernail dysplasia, patellar dysplasia, elbow deformities, and iliac horns, with a prevalence of 1 in 50,000 children. Most cases are caused by LMX1B mutations. Approximately 10%–40% of patients with NPS develop renal dysfunction in early childhood, whereas approximately 30% progress to end‐stage renal disease (ESRD). In addition, a few reports describe NPS without LMX1B mutations, but the mechanism affecting renal function is still unclear. In particular, nail‐patella‐like renal disease (NPLRD) presents solely with nephropathy without the physical changes that are characteristic of NPS. Herein, we report a case of clinicopathological NPLRD with characteristic NPS findings on electron microscopy but without physical features or LMX1B mutation, as confirmed by whole exome sequencing. The patient subsequently progressed to ESRD and underwent living‐related kidney transplantation. Seven years posttransplantation, no renal function‐related events occurred, and the patient returned to social activities without complications.

7 April 2026 in Oncology
Verified
Journal Article
Closed access
PDF file
TOTakaya Ohno
Takaya Ohno
YNYuki Nakajima
Yuki Nakajima
YYYuki Yoshikawa
Yuki Yoshikawa
TTTakuya Tsujino
Takuya Tsujino
RMRyoichi Maenosono
Ryoichi Maenosono
TITeruo Inamoto
Teruo Inamoto
Introduction: Bladder cancer (BC) is influenced by hypoxic conditions, which promote tumor progression and resistance to therapy. MicroRNAs (miRNAs) play key roles in regulating gene expression under hypoxia. Methods: This study utilized an miRNA array to compare expression profiles under normoxic and hypoxic conditions. We analyzed 1,024 miRNAs, focusing on differentially expressed miRNAs. Survival analysis was performed using a cohort of 408 BC patients from TCGA (The Cancer Genome Atlas). Target prediction for hypoxia-inducible factors (HIFs) and cancer-related genes was performed. Results: Of 1,024 miRNAs, 508 were downregulated and 516 upregulated in hypoxia. Four miRNAs (hsa-miR-210, hsa-miR-4435, hsa-miR-6875, hsa-miR-193b) were upregulated >50-fold, and four (hsa-miR-1250, hsa-miR-1288, hsa-miR-362, hsa-miR-6828) were downregulated. Upregulated miRNAs were associated with a trend toward improved overall survival in 408 BC patients (log-rank p = 0.049). Three downregulated miRNAs targeted HIF-1α, while three upregulated miRNAs targeted HIF-3α. Hsa-miR-210 targeted AGO2 and USP10, with hsa-miR-4435 also targeting AGO2. Conclusion: BC under hypoxia exhibits a specific miRNA profile targeting HIFs and cancer-related genes including AGO2 and USP10, potentially influencing treatment success and survival.